search
Include:
1 Research products, page 1 of 1

Relevance
arrow_drop_down
  • Open Access
    Authors: 
    R. Thomas Lumbers; Sonia Shah; Honghuang Lin; Tomasz Czuba; Albert Henry; Daniel I. Swerdlow; Anders Mälarstig; Charlotte Andersson; Niek Verweij; Michael V. Holmes; +156 more
    Publisher: Wiley
    Countries: France, France, United Kingdom, Sweden, Sweden, Denmark, Denmark, United Kingdom, United Kingdom, Netherlands
    Project: EC | BigData Heart (116074), EC | inHForm (679242)

    Abstract: Aims: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure. Methods and results: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome‐wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow‐up following heart failure diagnosis ranged from 2 to 116 months. Forty‐nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34–90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low‐frequency variants (allele frequency 0.01–0.05) at P < 5 × 10−8 under an additive genetic model. Conclusions: HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction. Funder: Department of Medicine, Boston University School of Medicine; Id: http://dx.doi.org/10.13039/100008748 Funder: National Heart, Lung, and Blood Institute; Id: http://dx.doi.org/10.13039/100000050 Funder: Knut and Alice Wallenberg Foundation; Id: http://dx.doi.org/10.13039/501100004063 Funder: NIHR UCLH Biomedical Research Centre; Id: http://dx.doi.org/10.13039/501100012317 Funder: Skåne University Hospital; Id: http://dx.doi.org/10.13039/501100011077 Funder: Evans Medical Foundation; Id: http://dx.doi.org/10.13039/100015927 Funder: Crafoord Foundation; Id: http://dx.doi.org/10.13039/501100003173 Funder: British Heart Foundation Cardiovascular Biomedicine Funder: Swedish National Health Service

Include:
1 Research products, page 1 of 1
  • Open Access
    Authors: 
    R. Thomas Lumbers; Sonia Shah; Honghuang Lin; Tomasz Czuba; Albert Henry; Daniel I. Swerdlow; Anders Mälarstig; Charlotte Andersson; Niek Verweij; Michael V. Holmes; +156 more
    Publisher: Wiley
    Countries: France, France, United Kingdom, Sweden, Sweden, Denmark, Denmark, United Kingdom, United Kingdom, Netherlands
    Project: EC | BigData Heart (116074), EC | inHForm (679242)

    Abstract: Aims: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure. Methods and results: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome‐wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow‐up following heart failure diagnosis ranged from 2 to 116 months. Forty‐nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34–90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low‐frequency variants (allele frequency 0.01–0.05) at P < 5 × 10−8 under an additive genetic model. Conclusions: HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction. Funder: Department of Medicine, Boston University School of Medicine; Id: http://dx.doi.org/10.13039/100008748 Funder: National Heart, Lung, and Blood Institute; Id: http://dx.doi.org/10.13039/100000050 Funder: Knut and Alice Wallenberg Foundation; Id: http://dx.doi.org/10.13039/501100004063 Funder: NIHR UCLH Biomedical Research Centre; Id: http://dx.doi.org/10.13039/501100012317 Funder: Skåne University Hospital; Id: http://dx.doi.org/10.13039/501100011077 Funder: Evans Medical Foundation; Id: http://dx.doi.org/10.13039/100015927 Funder: Crafoord Foundation; Id: http://dx.doi.org/10.13039/501100003173 Funder: British Heart Foundation Cardiovascular Biomedicine Funder: Swedish National Health Service

Send a message
How can we help?
We usually respond in a few hours.